PR Newswire Clinical TrialsOriginal article
AusperBio to Present Long-Term Follow-Up Data of AHB-137 Treatment in Chronic Hepatitis B in Two Late-Breaking Oral Presentations at AASLD The Liver Meeting® 2026
ConferenceAHB-137Positive
AI Analysis
Summary
AusperBio Therapeutics and Ausper Biopharma have been selected to present long-term follow-up data of AHB-137 for chronic hepatitis B treatment as late-breaking oral presentations at The Liver Meeting 2026.
Clinical Trial Data
Outcome Details
Long-term follow-up data selected for late-breaking oral presentations
Importance:5/10
Sentiment:
0.50
AHB-137chronic hepatitis Blong-term follow-upconference presentationAASLD Liver Meetinglate-breaking
Read the original article
Published by PR Newswire Clinical Trials on October 8, 2026 12:30 AM